Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesLaboratory/PathologyMutual of Omaha Flow Cytometry Coverage | OpenPaye…
    Ask Trek AI about this page
    ModifiedMutual of OmahaPolicy AHS - F2019 - Flow Cytometry

    Flow Cytometry

    Customize your policy alerts

    Sign up for mutualofomaha Policy AHS - F2019 - Flow Cytometry alerts

    Get alerted when Policy AHS - F2019 - Flow Cytometry changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage and reimbursement limitations for flow cytometry, including immunophenotyping, cell enumeration, and flow cytometry-derived DNA content or proliferative activity testing. Coverage applies according to the member’s benefit plan and applicable Medicare or Medicaid requirements.

    Policy Summary
    PayerMutual of Omaha
    PolicyFlow Cytometry
    Policy CodePolicy N/A
    Change TypeMaterial revision
    Effective DateNov 1, 2026
    Next Review DateN/A
    Key ActionDo not use codes 88187, 88188, and 88189 together for a single specimen in any combination.
    SourceLink
    POLICY UPDATE CHANGES

    CC2f was edited for clarity.

    CC2g was revised to include CPT codes 88184 and 88185 in the incompatibility rule to align with NCCI.

    The background, guidelines and recommendations, and evidence-based scientific references were updated.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    11
    Covered clinical indication categories for flow cytometry immunophenotyping
    35Maximum additional-marker units for code 88185 per date of service
    2Maximum first-marker units for code 88184 per date of service
    2Maximum specimens per date of service for codes 88187, 88188, or 88189
    Not coveredRoutine cancer DNA-content or proliferation testing for prognostic or therapeutic purposes
    2CPT codes added to the incompatibility rule

    Medical Necessity and Coverage Criteria

    Covered immunophenotyping indications

    Flow cytometry immunophenotyping of cell surface markers meets coverage criteria when ANY of the following indications is present.

    Covered indications

    • Cytopenic or hematologic disorders: The individual has cytopenias, lymphoma, leukemia, a myeloproliferative or lymphoproliferative disorder, or myelodysplastic syndrome.
    • B-cell monitoring is performed for an immunosuppressive disorder.
    • T-cell monitoring is performed for HIV infection or AIDS.
    • Mast cell neoplasm: The individual has a mast cell neoplasm.
    • Paroxysmal nocturnal hemoglobinuria: The individual has paroxysmal nocturnal hemoglobinuria.
    • Transplant monitoring: Testing is performed for preoperative or postoperative monitoring of an individual who will undergo or has undergone organ transplantation.
    • Plasma cell disorder: The individual has a plasma cell disorder.
    • Primary immunodeficiency: The individual has a primary immunodeficiency.
    • Primary platelet disorder: The individual has a non-neoplastic primary platelet disorder.
    • Red or white cell disorder: The individual has a non-neoplastic red cell or white cell disorder.
    • Gestational trophoblastic disease: The individual has gestational trophoblastic disease.

    Not medically necessary or unproven DNA content and S-phase testing

    The following service does not meet coverage criteria.

    Not covered cancer DNA or proliferation testing: Flow cytometry-derived DNA content, including DNA Index, or cell proliferative activity, including S-phase fraction or percent S-phase, is measured for prognostic or therapeutic purposes in the routine clinical management of cancer.

    The policy cites a lack of available published scientific literature confirming that the testing is required and beneficial for diagnosis and treatment.

    Clinical indications identified by Bethesda consensus

    The Bethesda consensus identifies flow cytometry as useful in any of the following clinical settings.

    Bethesda clinical settings

    • Cytopenias: Evaluation is being performed for cytopenias.
    • Elevated leukocyte count: Evaluation is being performed for an elevated leukocyte count.
    • Atypical cells or blasts: Evaluation is being performed for atypical cells or blasts.
    • Body fluids: Evaluation is being performed on a body-fluid specimen.

    Acute leukemia initial diagnostic evaluation

    For patients with suspected or confirmed acute leukemia, CAP and ASH strongly recommend a comprehensive diagnostic evaluation that includes flow cytometric immunophenotyping.

    Acute leukemia diagnostic workup

    • Classification panel: The flow cytometry panel is sufficient to distinguish acute myeloid leukemia, including acute promyelocytic leukemia; T-cell acute lymphoblastic leukemia, including early T-cell precursor leukemias; B-cell precursor acute lymphoblastic leukemia; and acute leukemia of ambiguous lineage.
    • Specimen availability: Sufficient bone marrow aspirate or peripheral blood material is available for flow cytometric immunophenotyping.

      If sufficient bone marrow aspirate or peripheral blood is not available, immunohistochemical studies may be used for limited immunophenotyping; a second unfixed bone marrow core biopsy may also be submitted for disaggregation for genetic studies and flow cytometry.

    Minimal residual disease and CSF evaluation

    For suspected or confirmed acute leukemia, flow cytometry may support additional evaluation and future disease monitoring.

    Acute leukemia monitoring capability

    • Comprehensive characterization: Flow cytometry analysis or molecular characterization is comprehensive enough to allow subsequent detection of minimal residual disease.
    • Additional evaluation: The pathologist uses flow cytometry for evaluation of cerebrospinal fluid, or the testing is intended to support subsequent minimal residual disease detection.

    Flow cytometry-derived DNA Index, S-phase fraction, or percent S-phase measurements used for prognostic or therapeutic purposes in the routine clinical management of cancer do not meet coverage criteria.

    The Bethesda recommendations indicate that flow cytometry is not indicated for mature neutrophilia, polyclonal hypergammaglobulinemia, polycythemia, thrombocytosis, or basophilia because these findings are generally not associated with hematolymphoid malignancy detectable by flow cytometry.

    Routine clinical use of flow cytometry-derived DNA content, including DNA Index, or cell proliferative activity, including S-phase fraction or percent S-phase, for cancer prognosis or treatment does not meet coverage criteria because sufficient published scientific literature confirming clinical benefit is not available.

    ASCO guidance states that flow-cytometrically derived DNA ploidy and DNA flow-cytometric proliferation analysis should not be used to determine the prognosis of early-stage colorectal cancer. Such testing should, at best, be considered experimental.

    ASCO reported insufficient evidence to support the routine clinical use of DNA ploidy determined by flow cytometry in breast cancer.

    For endometrial cancer, cited guidance reports that there are few definitive studies supporting routine use of ploidy analysis to determine prognosis. Although some literature suggests an association between ploidy and prognosis, definitive evidence of its prognostic impact is lacking, and additional prospective studies are needed.

    Covered Clinical Applications

    Covered flow cytometry immunophenotyping indications

    Coverage is available for flow cytometry immunophenotyping of cell surface markers when ANY of the following disease, monitoring, or diagnostic indications is present.

    Covered disease and monitoring categories

    • Hematologic neoplasia or cytopenias: The individual has cytopenias, lymphoma, leukemia, a myeloproliferative or lymphoproliferative disorder, or myelodysplastic syndrome.
    • Immune monitoring: The testing is for B-cell monitoring in an immunosuppressive disorder or T-cell monitoring for HIV infection or AIDS.
    • Other hematologic disorders: The individual has a mast cell neoplasm, paroxysmal nocturnal hemoglobinuria, plasma cell disorder, primary immunodeficiency, non-neoplastic primary platelet disorder, or non-neoplastic red cell or white cell disorder.

    Applicable Codes and Coding Categories

    Flow cytometric immunophenotyping for potential hematolymphoid neoplasiaCPTCovered
    88184Flow cytometric immunophenotyping for assessment of potential hematolymphoid neoplasia; first marker, per specimen
    88185Flow cytometric immunophenotyping for assessment of potential hematolymphoid neoplasia; each additional marker
    88186Flow cytometric immunophenotyping for assessment of potential hematolymphoid neoplasia
    88187Flow cytometry technical component or interpretation code for assessment of potential hematolymphoid neoplasia
    88188Flow cytometry technical component or interpretation code for assessment of potential hematolymphoid neoplasia
    88189Flow cytometry technical component or interpretation code for assessment of potential hematolymphoid neoplasia
    Cell enumerationCPTCovered
    86355Cell enumeration
    86356Cell enumeration
    86357Cell enumeration
    86359Cell enumeration
    86360Cell enumeration
    86361Cell enumeration
    86367Cell enumeration
    Applicable CPT/HCPCS Procedure CodesCPT
    86355B cells, total count
    86356Mononuclear cell antigen, quantitative (eg, flow cytometry), not otherwise specified, each antigen
    86357Natural killer (NK) cells, total count
    86359T cells; total count
    86360T cells; absolute CD4 and CD8 count, including ratio
    86361T cells; absolute CD4 count
    86367Stem cells (ie, CD34), total count
    88182Flow cytometry, cell cycle or DNA analysis
    88185Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; each additional marker (list separately in addition to code for first marker)
    88187Flow cytometry, interpretation; 2 to 8 markers
    1–10 of 12
    1/2
    Coding Limit
    Code88184
    ServiceFirst marker per specimen for flow cytometric immunophenotyping assessing potential hematolymphoid neoplasia
    Maximum2 units per date of service
    Coding Limit
    Code88185
    ServiceEach additional marker for flow cytometric immunophenotyping assessing potential hematolymphoid neoplasia
    Maximum

    Provider and Billing Requirements

    Billing Rule

    Use Diagnostically Relevant Markers

    When a neoplasm has an established immunophenotype, limit subsequent testing to markers that are diagnostically relevant to that neoplasm.

    Denial Risk

    Routine Cancer DNA-Content or Proliferation Testing Not Covered

    Routine measurement of flow cytometry-derived DNA content or cell proliferative activity does not meet coverage criteria when performed for prognostic or therapeutic purposes in the routine clinical management of cancers.

    • DNA Index
    • S-phase fraction or percentage of S-phase

    Unit and Specimen Limits

    Frequency Limit
    Code88184
    DescriptionFirst marker per specimen for flow cytometric immunophenotyping assessing potential hematolymphoid neoplasia
    Maximum2 units per date of service
    Frequency Limit
    Code88185
    DescriptionEach additional marker for flow cytometric immunophenotyping assessing potential hematolymphoid neoplasia
    Maximum35 units per date of service

    Noncovered and Unsupported Uses

    Not covered: Flow cytometry-derived DNA Index, S-phase fraction, or percent S-phase measurement when used for prognostic or therapeutic purposes in the routine clinical management of cancer.

    Not covered: Routine prognostic use of flow-cytometric DNA ploidy or S-phase fraction in early-stage colorectal cancer is not supported. ASCO states that these tests should not be used to determine prognosis and should, at best, be considered experimental.

    Not covered: Routine clinical use of flow-cytometric DNA ploidy or S-phase fraction for prognostic decision-making in cancer is unsupported when evidence is insufficient to establish clinical benefit.

    Not covered: Additional routine prognostic use of flow-cytometric DNA ploidy or S-phase fraction is unsupported where authoritative guidance identifies insufficient or nondefinitive evidence, including breast and endometrial cancer.

    Flow Cytometry Background

    Flow cytometry analyzes the optical light-scattering and fluorescence characteristics of individual cells or particles. This allows assessment of properties such as size, shape, viability, granularity, cell counts, and biomarkers. Immunophenotyping is commonly used to identify cellular markers and characterize hematologic and immune disorders; flow cytometry is also used in transplantation monitoring, immunodeficiency evaluation, and assessment of hematolymphoid neoplasia.

    Acronyms and Terminology

    Definitions
    AbbreviationFCI
    Full termFlow cytometric immunophenotyping
    Terminology categoryFlow cytometry testing terminology
    Definitions
    AbbreviationMFC
    Full termMultiparameter (multicolor) flow cytometry
    Terminology categoryFlow cytometry testing terminology
    Policy Summary
    PayerMutual of Omaha
    PolicyFlow Cytometry
    Policy CodePolicy N/A
    Change TypeMaterial revision
    Effective DateNov 1, 2026
    Next Review DateN/A
    Key ActionDo not use codes 88187, 88188, and 88189 together for a single specimen in any combination.
    SourceLink
    On This Page
    Medical Necessity and Coverage CriteriaCovered Clinical ApplicationsApplicable Codes and Coding CategoriesProvider and Billing RequirementsUnit and Specimen LimitsNoncovered and Unsupported UsesFlow Cytometry BackgroundAcronyms and Terminology
    Plasmacytosis or monoclonal gammopathy: Evaluation is being performed for plasmacytosis or monoclonal gammopathy.
  1. Organomegaly or tissue masses: Evaluation is being performed for organomegaly or tissue masses.
  2. Patient monitoring: The testing is for a patient-monitoring indication identified by the Bethesda recommendations.
  3. Transplant monitoring: The testing is for preoperative or postoperative monitoring of an individual who will undergo or has undergone organ transplantation.
  4. Gestational trophoblastic disease: The individual has gestational trophoblastic disease.
  5. Bethesda clinical settings

    The Bethesda consensus identifies flow cytometry as useful in any of the following clinical settings.

    • Cytopenias: Evaluation is being performed for cytopenias.
    • Elevated leukocyte count: Evaluation is being performed for an elevated leukocyte count.
    • Atypical cells or blasts: Evaluation is being performed for atypical cells or blasts.
    • Body fluids: Evaluation is being performed on a body-fluid specimen.
    • Plasmacytosis or monoclonal gammopathy: Evaluation is being performed for plasmacytosis or monoclonal gammopathy.
    • Organomegaly or tissue masses: Evaluation is being performed for organomegaly or tissue masses.
    • Patient monitoring: The testing is for a patient-monitoring indication identified by the Bethesda recommendations.

    Suspected myelodysplastic syndromes

    Comprehensive immunophenotyping is covered for evaluation of suspected myelodysplastic syndromes.

    Suspected myelodysplastic syndrome

    • Clinically relevant findings: Flow cytometry findings may indicate multilineage dysplasia, or a small population of myeloid progenitors has multiple immunophenotypic aberrant features.

      Findings may contribute to individual risk assessment, including recognition of small aberrant myeloid progenitor populations and risk of progression to acute myeloid leukemia.

    Acute leukemia initial diagnostic workup

    Flow cytometric immunophenotyping is covered as part of the initial diagnostic workup and classification of acute leukemia.

    Acute leukemia classification

    • Required classification capability: The flow cytometry panel is sufficient to distinguish acute myeloid leukemia, including acute promyelocytic leukemia; T-cell acute lymphoblastic leukemia, including early T-cell precursor leukemias; B-cell precursor acute lymphoblastic leukemia; or acute leukemia of ambiguous lineage.

    Platelet disorders and platelet function testing

    Flow cytometric analysis is covered for evaluation or monitoring of inherited or acquired platelet disorders when an appropriately designed assay is used.

    Platelet disorder or function indication

    • Surface glycoprotein deficiency: The testing evaluates an inherited or acquired deficiency of platelet surface glycoproteins, including Bernard-Soulier syndrome, Glanzmann thrombasthenia, or inherited or immune-mediated GPVI defects.
    • Alpha granule secretion defect: The testing evaluates a platelet alpha granule secretion defect, such as gray platelet syndrome.
    • Activation or signaling defect: The testing evaluates a defect in a specific platelet activation or signaling pathway, such as a RASGRP2, P2Y12, or TXA2R disorder.
    • GFI1B macrothrombocytopenia: The testing evaluates GFI1B macrothrombocytopenia associated with platelet expression of CD34.
    • Platelet procoagulant disorder: The testing evaluates a disorder of platelet procoagulant activity, such as Scott syndrome or Stormorken syndrome.
    • Increased platelet activation: The testing assesses increased platelet activation in a prothrombotic syndrome, diabetes, antiphospholipid syndrome, or drug-induced non-immune platelet activation.
    • P2Y12 antagonist monitoring: The testing monitors the pharmacodynamic effect of a P2Y12 antagonist, including ticlopidine, clopidogrel, prasugrel, ticagrelor, or cangrelor, using a specifically designed test such as VASP P2Y12.
    • Immature platelet fraction: The testing determines the fraction of immature platelets.

    Myeloperoxidase expression assessment

    Assessment of myeloperoxidase expression is covered when needed for classification of selected acute leukemias under the 2022 WHO Classification of Haematolymphoid Tumours.

    Selected acute leukemia classifications

    • AML with minimal differentiation: The evaluation concerns acute myeloid leukemia with minimal differentiation.
    • Mixed-phenotype acute leukemia: The evaluation concerns T/myeloid mixed-phenotype acute leukemia.
    • Early T-precursor leukemia: The evaluation concerns early T-precursor lymphoblastic leukemia/lymphoma.
    35 units per date of service
    Interpretation-Code Limit
    Codes88187, 88188, and 88189
    ServiceFlow cytometry interpretation
    Reporting limit1 unit per specimen
    Specimen Limit
    Codes88187, 88188, and 88189
    PeriodPer date of service
    Specimen maximum2 specimens per date of service
    Cell Enumeration Limit
    Codes86355, 86357, 86359, 86360, 86361, and 86367
    ServiceCell enumeration
    Reporting limitSingle units only
    Billing Rule

    Do Not Combine Interpretation Codes

    Do not report codes 88187, 88188, and 88189 together in any combination for a single specimen.

    • Apply the restriction per specimen.
    Denial Risk

    Do Not Combine Immunophenotyping and Enumeration Codes

    Do not report flow cytometric immunophenotyping and cell-enumeration codes together.

    • Do not use codes 88184–88189 in conjunction with 86355, 86356, 86357, 86359, 86360, 86361, or 86367.
    • Use 86355, 86357, 86359, 86360, 86361, or 86367 for cell enumeration; these codes are reimbursable as single units only.
    Billing Rule

    Apply Unit and Specimen Limits

    Apply the unit and specimen limits for flow cytometry reimbursement codes.

    • 88184: first marker per specimen; reimbursable up to 2 units per date of service.
    • 88185: each additional marker; reimbursable up to 35 units per date of service.
    • 88187, 88188, and 88189: reimbursed at 1 unit per specimen, with a maximum of 2 specimens per date of service.
    Frequency Limits
    Codes88187, 88188, and 88189
    Units1 unit per specimen
    Specimen limitMaximum of 2 specimens per date of service
    Frequency Limit
    Codes86355, 86357, 86359, 86360, 86361, and 86367
    ServiceCell enumeration
    UnitsSingle units only
    Definitions
    AbbreviationMRD
    Full termMinimal residual disease
    Terminology categoryFlow cytometry testing terminology
    Definitions
    AbbreviationPID
    Full termPrimary immunodeficiency
    Terminology categoryClinical terminology
    Definitions
    AbbreviationSPF
    Full termS-phase fraction
    Terminology categoryFlow cytometry testing terminology
    Definitions
    AbbreviationCLIA '88
    Full termClinical Laboratory Improvement Amendments of 1988
    Policy contextRegulatory framework for high-complexity laboratory-developed tests
    Definitions
    AbbreviationCAP
    Full termCollege of American Pathologists
    Terminology categoryClinical and laboratory organization terminology